Assessing mean apnea-hypopnea duration (MAD) in patients with OSA yields hypoxemia and symptom burden data not provided by the AHI or ODI.

At World Sleep 2025, Robson Capasso, MD, of Stanford University in California, challenged the field's reliance on the apnea-hypopnea index (AHI) as the primary measure of treatment success in ...

Two randomized controlled trials show reduction in AHI; significant improvements seen in all secondary end points. (HealthDay News) — Tirzepatide reduces the apnea-hypopnea index (AHI) among ...

Sunrise Group, a pioneer in medical device innovation and sleep care, today announced a new peer-reviewed study in Nature Communications Medicine. Sunrise developed the only home sleep test with ...

Early management of obstructive sleep apnea in patients with IPF could slow disease progression and improve outcomes.

Mirroring results reported in a phase IIb study, Apnimed Inc.’s first of two pivotal trials testing AD-109 as an oral therapy in obstructive sleep apnea hit primary and secondary endpoints. Should ...